1:21 PM
 | 
Aug 18, 2017
 |  BioCentury  |  Finance

Close affiliation

What Seattle-based Just Biotherapeutics gains from Just China's series B

A fresh investment in antibody manufacturing capacity in China will enable both Seattle-based Just Biotherapeutics Inc. and its affiliate Hangzhou Just Biotherapeutics Ltd. to scale up for late stage trials and commercial launches.

The U.S. company, which holds an undisclosed stake in the Hangzhou affiliate, has technology for low-cost antibody production, as well as a pilot GMP manufacturing plant and an undisclosed pipeline.

Hangzhou Just Biotherapeutics, or “Just China” for short, announced on Aug. 8 the close of a $57 million series B round to complete construction of a new facility in 1Q18. The round also will get two to three undisclosed antibodies from Just China’s own pipeline into the clinic next year.

Temasek led the financing, joined by fellow new investors Taikang, Hangzhou Economic & Technological...

Read the full 629 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >